CoVaccine HT™ adjuvant is superior to Freund's adjuvants in eliciting antibodies against the endogenous alarmin HMGB1.
Adjuvants are used to enhance the immune response against specific antigens for the production of antibodies, with the choice of adjuvant most critical for poorly immunogenic and self-antigens. This study quantitatively and qualitatively evaluated CoVaccine HT™ and Freund's adjuvants for eliciting therapeutic ovine polyclonal antibodies targeting the endogenous alarmin, high mobility group box-1 (HMGB1). Sheep were immunised with HMGB1 protein in CoVaccine HT™ or Freund's adjuvants, with injection site reactions and antibody titres periodically assessed. The binding affinity of antibodies for HMGB1 and their neutralisation activity was determined in-vitro, with in vivo activity confirmed using a murine model of endotoxemia. Results indicated that CoVaccine HT™ elicited significantly higher antibody tires with stronger affinity and more functional potency than antibodies induced with Freund's adjuvants. These studies provide evidence that CoVaccine HT™ is superior to Freund's adjuvants for the production of antibodies to antigens with low immunogenicity and supports the use of this alternative adjuvant for clinical and experimental use antibodies.
Experimental Therapeutics Laboratory, Hanson Institute and Sansom Institute, School of Pharmacy and Medical Science, University of South Australia, SA, 5000, Australia; Robinson Research Institute, Discipline of Obstetrics and Gynaecology, School of Medicine, The University of Adelaide, SA, 5005, Australia.
Nerissa
N
Lakhan
Experimental Therapeutics Laboratory, Hanson Institute and Sansom Institute, School of Pharmacy and Medical Science, University of South Australia, SA, 5000, Australia.
Natalie E
NE
Stevens
Experimental Therapeutics Laboratory, Hanson Institute and Sansom Institute, School of Pharmacy and Medical Science, University of South Australia, SA, 5000, Australia; Robinson Research Institute, Discipline of Obstetrics and Gynaecology, School of Medicine, The University of Adelaide, SA, 5005, Australia. Electronic address: kerrilyn.diener@adelaide.edu.au.
Kerrilyn R
KR
Diener
Experimental Therapeutics Laboratory, Hanson Institute and Sansom Institute, School of Pharmacy and Medical Science, University of South Australia, SA, 5000, Australia; Robinson Research Institute, Discipline of Obstetrics and Gynaecology, School of Medicine, The University of Adelaide, SA, 5005, Australia. Electronic address: john.hayball@unisa.edu.au.
John D
JD
Hayball
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D057134:Antibodies, Neutralizing / Q000096:biosynthesis* / Q000097:blood / Q000276:immunology; D000915:Antibody Affinity; D004195:Disease Models, Animal; D019446:Endotoxemia / Q000097:blood / Q000139:chemically induced / Q000276:immunology; D005620:Freund's Adjuvant / Q000008:administration & dosage / Q000276:immunology*; D024243:HMGB1 Protein / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism; D007114:Immunization; D008070:Lipopolysaccharides; D008810:Mice, Inbred C57BL; D034561:Sheep, Domestic; D013997:Time Factors
D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D024243:HMGB1 Protein; C585491:HMGB1 protein, human; D008070:Lipopolysaccharides; D005620:Freund's Adjuvant
Adjuvant; Antibody; Antibody production; CoVaccine HT™; HMGB1